생리활성물질 S-627(A)와 S-627(B)의 분리

Isolation of S-627(A) and (B) as Candidates of Anticandiosis Agent

  • 이상한 (경북대학교 미생물학과) ;
  • 이동선 (경북대학교 미생물학과) ;
  • 서영배 (경북대학교 미생물학과) ;
  • 김종국 (경북대학교 미생물학과) ;
  • 홍순덕 (경북대학교 미생물학과)
  • 발행 : 1997.09.01

초록

수정된 선별법(modified selection method)을 사용하여 candiosis에 대한 새로운 생리활성물질(anticandiosis agent)을 생성하는 미생물을 분리하여Streptomyces sp. S627이라 명명하였으며, 이균의 발효액으로부터 methanol추출, diaion Hp-20, silica gel chromatography, 및 분취용 TLC 등의 방법을 사용하여 물리화학적 특성이 다른 S-637(A)와 S-627(B)을 분리하였다.

In order to select new anticandiosis agent-producing candidates, we used a modified selection method. Two active fractions designated as S-6279A) and (B) were isolated from the fermentation broth of Streptomycetes sp. S627 which was screened by methanol extraction, diaion HP-20 and silica gel column chromatography (chloroform-me-thanol, and benzene-ethyl acetate), and preparative thin layer chromatography.

키워드

참고문헌

  1. CAB International Opportunistic Mycoses of Man and Other Animals Smith, J. M. B.
  2. J. Antimicrob. Chemother. v.28 no.S Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host Denning, D. W.
  3. J. Antimicrob. Chemother. v.28 no.S Overview of the treatment of disseminated fungal infections. Hay, R. J.
  4. J. Antimicrob. Chemother. v.28 no.S Amphotericin B : an introduction. Warnock, D. W.
  5. J. Antimicrob. Chemother. v.28 no.S Experience with liposomal amphotericin B (AmBisome) in cryptococcal meningitis in AIDS. Coker, R. J.;Murphy, S. M.;Harris, J. R.
  6. J. Infect. Diseases v.157 Cryptococcal meningitis in patients with AIDS. Dismukes, W. E.;Sande, M. A.
  7. N. Eng. J. Med. v.321 Infections with Cryphtococcus neoformans in the acquired immunodeficiency syndrome. Chuck, S. L.;Sande, M. A.
  8. Ann. Internal Med. v.103 Are corticosteroids beneficial as adjunctive therapy for Pneumocystis pneumonia in AIDS ? Kovacs, J. A.;Masur, H.
  9. J. Antimicrob. Chemother. v.28 no.S Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. Ringden, O.;Meunier, F.;Tollemar, J.;Ricci, P.;Tura, S.;Kuse, E.;viviani, M. A.;Gorin, N. C.;Klastersky, J.;Funaux, P.
  10. Program and Abstract of the 4th International Conference on AIDS Salzman, B. R.;Friedland, G. H.;Klein, R. S.;Vileno, J.;Freeman, K.;Schager, L. K.
  11. J. Ann. Internal Med. v.104 Makintenance amphotericin B for cryptococcal meningitis in the acquired immunodeficiency syndrome (AIDS). Zuger, A.;Louie, R. S.;Holzman, M. S.;Simberkoff, M. S.;Rahal, J.
  12. Adv. Microb. Physiol. v.27 Mode of action of clinically important antifungal drugs. Kerridge, D.
  13. Antimicrob. Ag. Chemother. v.34 Amphotericin B : current understanding of mechnisms of action. Brajtburg, J. W.;Powerly, W. G.;Kobayashi, G. S.;Medoff, G.
  14. Intl. J. Syst. Bacteriol. v.16 The Streptomyces nonmenclature. Shrirling, E. B.;Gottlieb, D.
  15. The Actinomycetes v.2 Waksman, S. A.
  16. Bergeys Manual of Systematic Bacteriology v.4 Williams, S. T.;Goodfellow, M.;Anderson, G.